- €2.58bn
- €3.06bn
- $3.84bn
- 71
- 74
- 18
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 8.5 | ||
| PEG Ratio (f) | 5.39 | ||
| EPS Growth (f) | 1.6% | ||
| Dividend Yield (f) | 3.81% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.42 | ||
| Price to Tang. Book | 6.33 | ||
| Price to Free Cashflow | 8.27 | ||
| Price to Sales | 0.77 | ||
| EV to EBITDA | 8.92 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.32% | ||
| Return on Equity | 7.83% | ||
| Operating Margin | 6.11% | ||
Financial Summary
| Year End 4th Jan | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4,359.39 | 4,960.43 | 5,943.7 | 5,425.4 | 3,839.7 | 3,857.23 | 3,987.57 | -2.4% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -23.98 | +27.19 | +22.04 | +10.21 | +16.32 | -1.82 | +10.24 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Glanbia plc is an Ireland-based nutrition company. The Company’s segments include Glanbia Performance Nutrition and Glanbia Nutritionals. The Glanbia Performance Nutrition segment manufactures and sells sports nutrition and lifestyle nutrition products through a variety of channels, including specialty retail, online, Food, Drug, Mass, Club (FDMC), and gyms in a variety of formats, including powders, ready-to-eat (bars and snacking foods) and ready-to-drink beverages. The Glanbia Nutritionals segment manufactures and sells cheese, dairy and non-dairy nutritional and functional ingredients, and vitamin and mineral premixes targeting the increased market focus on health and nutrition. The Glanbia Nutritionals segment also includes the flavors business. The Company provides flavors and extracts to the food and beverage industries, with a focus on organic and natural ingredients. Its portfolio of brands includes Optimum Nutrition, Isopure, Nutramino, SlimFast, think!, and others.
Directors
- Donard Gaynor NEC (64)
- Mark Garvey FID (56)
- Jim Bergin CEX (58)
- Hugh McGuire CEX (50)
- Brian Phelan CEX (54)
- Siobhan Talbot MDR (57)
- Michael Patten DHR (58)
- Michael Horan SEC (56)
- Patsy Ahern NED (63)
- Roisin Brennan NED (56)
- Vincent Gorman NED (64)
- Brendan Hayes NED (60)
- John Murphy NED (61)
- John Murphy NED (61)
- Patrick Murphy NED (62)
- Patrick Coveney NID (50)
- Jane Lodge NID (65)
- Daniel O'Connor NID (62)
- Last Annual
- January 4th, 2025
- Last Interim
- January 4th, 2025
- Incorporated
- March 10th, 1988
- Public Since
- March 1st, 1988
- No. of Employees
- 5,791
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
London Stock Exchange- Shares in Issue
- 255,612,399
- Address
- Glanbia House, Ring Road, KILKENNY
- Web
- https://www.glanbia.com/
- Phone
- +353 567772200
- Contact
- Liam Hennigan
- Auditors
- Deloitte Ireland LLP
Latest News for GLB
Upcoming Events for GLB
Q1 2025 Glanbia PLC Interim Management Statement Release
Glanbia PLC Annual Shareholders Meeting
Half Year 2025 Glanbia PLC Earnings Release
Similar to GLB
Anglo-Eastern Plantations
London Stock Exchange
Anpario
London Stock Exchange
Associated British Foods
London Stock Exchange
Bakkavor
London Stock Exchange
Benchmark Holdings
London Stock Exchange
FAQ
As of Today at 20:50 UTC, shares in Glanbia are trading at €9.75. This share price information is delayed by 15 minutes.
Shares in Glanbia last closed at €9.75 and the price had moved by -42.31% over the past 365 days. In terms of relative price strength the Glanbia share price has underperformed the FTSE All Share Index by -44.57% over the past year.
The overall consensus recommendation for Glanbia is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreGlanbia does not currently pay a dividend.
Glanbia does not currently pay a dividend.
Glanbia does not currently pay a dividend.
To buy shares in Glanbia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €9.75, shares in Glanbia had a market capitalisation of €2.58bn.
Here are the trading details for Glanbia:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: GLB
Based on an overall assessment of its quality, value and momentum Glanbia is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Glanbia is €12.24. That is 25.49% above the last closing price of €9.75.
Analysts covering Glanbia currently have a consensus Earnings Per Share (EPS) forecast of $1.27 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Glanbia. Over the past six months, its share price has underperformed the FTSE All Share Index by -39.22%.
As of the last closing price of €9.75, shares in Glanbia were trading -32.61% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Glanbia PE ratio based on its reported earnings over the past 12 months is 8.5. The shares last closed at €9.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Glanbia's management team is headed by:
- Donard Gaynor - NEC
- Mark Garvey - FID
- Jim Bergin - CEX
- Hugh McGuire - CEX
- Brian Phelan - CEX
- Siobhan Talbot - MDR
- Michael Patten - DHR
- Michael Horan - SEC
- Patsy Ahern - NED
- Roisin Brennan - NED
- Vincent Gorman - NED
- Brendan Hayes - NED
- John Murphy - NED
- John Murphy - NED
- Patrick Murphy - NED
- Patrick Coveney - NID
- Jane Lodge - NID
- Daniel O'Connor - NID